HIV and COVID‑Vax: Why Some People Respond Differently

People with HIV who are on antiretroviral therapy can still have a varied reaction to COVID‑19 vaccines. Researchers studied this by looking at how active the immune system is before vaccination and whether that predicts how well the vaccine works. The study included several clinics across different regions, gathering data from many participants in one forward‑looking effort. First, scientists measured markers that show inflammation and immune activation in the blood of participants who already had HIV. They then compared those results with a group of people without HIV, all of whom received the same vaccine schedule. The findings revealed that individuals with HIV show a wide range of baseline immune activity. Some had high levels of inflammation, while others were relatively calm.When vaccinated, those with higher baseline activation tended to develop weaker antibody responses compared to their peers without HIV. In contrast, people with lower baseline inflammation generally mounted stronger vaccine‑induced immunity. This pattern was not seen in the HIV‑negative group, where immune responses were more uniform across participants. The study suggests that the state of the immune system before vaccination can influence how well a COVID‑19 vaccine works in people living with HIV. It also points to the possibility of tailoring vaccination strategies—such as timing or additional booster doses—for those with higher inflammation. Overall, the research highlights that even when HIV is controlled by medication, underlying immune differences can affect vaccine effectiveness. Future work may focus on identifying specific inflammatory markers that could guide personalized vaccination plans.